Hepatitis C Drug Market Size, Share, Growth Report 2032

Hepatitis C Drug Market Insights

According to a report from Zion Market Research, the global Hepatitis C Drug Market was valued at USD 25.68 Billion in 2023 and is projected to hit USD 38.67 Billion by 2032, with a compound annual growth rate (CAGR) of 4.2% during the forecast period 2024-2032. This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Hepatitis C Drug Market industry over the next decade.

Global Hepatitis C Drug Market: Overview 

The global Hepatitis C Drug market size accounted for USD 20.5 Billion in 2020 and is expected to reach USD 69.1 Billion by 2028, growing at a CAGR of around 16.3% between 2021 and 2028.    

Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting headaches, poor appetite, joint pain, and clay-colored stools.

Hepatitis C is a significant public health concern that affected more than 400.2 Million patients globally in 2019. Even more alarming, only 0.4 Million were treated per year, showing the need for increased screening and timely diagnosis.

Request Free Sample

The partnerships and mergers and acquisitions of players in the Hepatitis C Drug market are also set to propel the market growth. For example, in April 2019, U.S. FDA announced the approval of Mavyret by AbbVie as the first-ever treatment approved for pediatric patients of all genotypes of hepatitis C.

Request Free Sample

COVID-19 Impact Analysis:

The lockdowns imposed by various countries to contain the spread of Covid-19 has impacted the global operations and supply chain which had negative consequences on the Hepatitis C Drug market as global sales declined. As healthcare professionals increasingly direct their resources towards caring for coronavirus-infected patients, other health issues are being relegated to the back seat. The players in the industry have temporarily suspended the production of Hepatitis C drugs in order to cater to coronavirus patients.

The significant decrease in the global Hepatitis C Drug market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.   

Growth Factors

The global hepatitis C drug market was likely to see development in the near future owing to an increase in the occurrence of HCV all over the world. In addition to this, lack of awareness is believed as a major fostering factor that promotes the growth of the hepatitis C drug market. Moreover, many lifestyle-associated factors, such as transferring of body fluid, unsafe sex, and having multiple sex partners are likely to propel the development of the hepatitis C drug market. On the other hand, lack of information and awareness about HCV, threat-related to the development & regulation of drugs, and treatment costs might hinder the development of the hepatitis C drug market.

Nevertheless, new efficient treatments are likely to bring growth opportunities to the hepatitis C market in the foreseeable future. For example, in April 2018, a nonprofit organization made a new hepatitis C medication that is just as effective as those made by other drug giants. This is supposed to bolster the development of the hepatitis C drug market.

Hepatitis C Drug Market: Report Scope

Segment Analysis Preview  

The hepatitis C drug market is divided based on end-users into five types such as private labs, hospitals, public health labs, physician offices, and blood banks. These sectors are the major end-users of the global hepatitis C drug market. In terms of income, hospitals were the dominating end-user recently and the same is anticipated to be the fastest and biggest developing sector in the hepatitis C drug market during the forecast period.

Regional Preview:

North America was the dominating market for hepatitis C drug market in terms of income owing to the broad accessibility of hospitals. Moreover, lifestyle-associated factors such as unprotected sex and having multiple sex partners have become very ordinary in European nations and North America. Furthermore, hepatitis C drug has huge growth avenues in emerging regions such as Latin America and the Asia Pacific due to government initiatives, the rising number of patients suffering from HCV, and healthcare infrastructure.

Request Free Sample

Key Market Players & Competitive Landscape

The major players operating the Hepatitis C Drug market are Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson, and Bristol-Myers Squibb.

Request Free Sample

To know more about this sample, Request For Customization.

The global Hepatitis C Drug market is segmented as follows:  

By End-User

• Hospitals
• Private labs
• Physician offices
• Public health labs
• Blood Bank

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa